

Prof. HAKAN AKBULUT

Personal Information

Office Phone: [+90 312 595 7112](tel:+903125957112)

Web: <https://avesis.ankara.edu.tr/100323>

International Researcher IDs

ORCID: 0000-0003-1631-5739

ScopusID: 7005749971

Yoksis Researcher ID: 9100

Education Information

Post Doctorate of Medicine, Ankara University, Ankara Tıp Fakültesi, Turkey 1993 - 1996

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, Ankara Dışkapı Yıldırım Beyazıt Eğitim Ve Araştırma Hastanesi, Turkey 1988 - 1993

Undergraduate, Hacettepe University, Tıp Fakültesi, Turkey 1982 - 1988

Foreign Languages

English, C1 Advanced

Research Areas

Health Sciences, Internal Medicine Sciences, Oncology

Academic Titles / Tasks

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2003 - Continues

Academic and Administrative Experience

Ankara University, 2018 - Continues

Courses

KANSER GELİŞİMİ VE METASTAZ BİYOLOJİSİ, Undergraduate, 2017 - 2018, 2015 - 2016

TÜMÖR İMMÜNOLOJİSİ, Postgraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015

İleri KAnser Araştırma Teknikleri, Doctorate, 2017 - 2018

MAKALE SAATİ, Postgraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015

KANSERLİ HASTALARDA ENFEKSİYON VE HEMATOLOJİK SORUNLAR, Undergraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016

GASTROİNTESTİNAL SİSTEM KANSERLERİ, Undergraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 -

2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009, 2007 - 2008, 2006 - 2007

İleri Tümör İmmünolojisi, Doctorate, 2017 - 2018

KANSER HÜCRESİNİN MOLEKÜLER VE BİYOLOJİK ÖZELLİKLERİ, Postgraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015

KANSER ARAŞTIRMA TEKNİKLERİ, Postgraduate, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015

KANSER GELİŞİMİ VE METASTAZ BİYOLOJİSİ, Postgraduate, 2016 - 2017

Klinik kanser konferansları, Postgraduate, 2015 - 2016, 2014 - 2015

Advising Theses

AKBULUT H., Rutin tedavi olarak bevacizumab kullanılan metastatik kolorektal kanserli kolorektal kanserli hastalarda tedavi etkinliğinin belirlenmesinde biyobelirteçlerin rolü, Expertise In Medicine, B.AKAY(Student), 2018

AKBULUT H., Kanser hücrelerinde anjiyogenik faktörlerin ekspresyonuna kemoterapinin etkilerinin incelenmesi, Postgraduate, M.ÖÇAL(Student), 2017

AKBULUT H., Anti-anjiyogenik ilaç tedavisinin tümör immünitesi üzerindeki etkilerinin araştırılması, Postgraduate, S.ABDİ(Student), 2017

AKBULUT H., Tümör hücrelerindeki PD-L1 ekspresyonunun anjiyogenez ve invazyon üzerine etkisi, Postgraduate, C.BABAHAN(Student), 2017

AKBULUT H., Metronomik kemoterapinin endotel hücre fonksiyonları üzerindeki etkisi, Postgraduate, F.GİZEM(Student), 2017

AKBULUT H., Bevasizumab alan metastatik kolon kanserli olgularda CEA ve histopatolojik özelliklerin değerlendirilmesi, Expertise In Medicine, F.SENA(Student), 2016

AKBULUT H., Bakuloviral vektörler aracılı sitokin ve intihar gen tedavileri, Doctorate, S.HANDE(Student), 2015

AKBULUT H., Metastatik kolorektal kanserli hastalarda setuksimab ve bevasizumabın etkinliğinin değerlendirilmesi retrospektif çalışma, Expertise In Medicine, Ö.GERÇİK(Student), 2014

AKBULUT H., Kolorektal kanserli hastalarda kök hücre gen ekspresyon profili ve prognostik önemi, Postgraduate, S.ÖZTOP(Student), 2013

AKBULUT H., Tamoksifen direncinde survivin gen ekspresyonunun klinik önemi, Expertise In Medicine, İ.DEDE(Student), 2013

AKBULUT H., Mide kanserinde kemoterapi yanıtı ve direncinde osteopontinin rolü, Expertise In Medicine, O.YAZICI(Student), 2011

AKBULUT H., Kolorektal kanserli hastalarda karaciğer metastazlarını saptamada serum golgi protein 73'ün yeri, Post Doctorate of Medicine, F.GÜZE(Student), 2011

AKBULUT H., Kanserde damar endoteline yönelik gen tedavisi ajanları geliştirilmesi, Doctorate, P.BAYDIN(Student), 2011

AKBULUT H., Kemoterapinin kolon kanseri, meme kanseri ve mide kanserinde VEGF düzeylerine etkisinin in vivo ve in vitro incelemesi, Postgraduate, S.HANDE(Student), 2010

AKBULUT H., Küçük hücreli dışı akciğer kanserinde tedaviye yanıt ile serum EGFR düzeyi arasındaki ilişki, Expertise In Medicine, İ.TEK(Student), 2005

AKBULUT H., Meme kanserinde serum telomeraz aktivitesi ve kemoterapi direncinin belirlenmesinde ve hastalık prognozundaki rolü, Expertise In Medicine, Ş.TEMİZKAN(Student), 2003

AKBULUT H., Kolorektal kanserlerde anjiyogenetik faktörlerin prognostik önemi, Expertise In Medicine, F.ALTUNTAŞ(Student), 2000

AKBULUT H., İleri evre mide kanserli hastalarda kronoterapinin yaşam kalitesi üzerine etkisinin araştırılması: Prospektif randomize "cross-over" çalışma, Expertise In Medicine, B.YALÇIN(Student), 1999

Published journal articles indexed by SCI, SSCI, and AHCI

1. **Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients.**

Eylemer Mocan E., Yekedüz E., Karataş G., Yazgan S. C., Köksoy E. B., Çay Şenler F., Utkan G., Demirkazık A., Akbulut H., Ürün Y.

Anti-cancer drugs, 2023 (SCI-Expanded)

- II. **A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus**
KÖKSOY E. B., AKBULUT H.
ANTI-CANCER DRUGS, vol.34, no.10, pp.1193-1195, 2023 (SCI-Expanded)
- III. **The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes**
BABAHAN C., Abdi Abgarmi S., SONUGÜR F. G., Öçal M., AKBULUT H.
TURKISH JOURNAL OF BIOLOGY, vol.47, no.4, pp.262-275, 2023 (SCI-Expanded)
- IV. **Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing**
Sonugür F. G., Babahan C., Abdi Abgarmi S., Akbulut H.
MOLECULAR BIOTECHNOLOGY, vol.65, no.7, pp.1129-1139, 2023 (SCI-Expanded)
- V. **Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors**
Yekeduz E., KÖKSOY E. B., YAZGAN S. C., KARATAŞ G., ÇAY ŞENLER F., UTKAN G., AKBULUT H., DEMİRKAZIK A., ÜRÜN Y.
ANTI-CANCER DRUGS, vol.33, no.10, pp.1145-1149, 2022 (SCI-Expanded)
- VI. **SIRT2 and FOXO3a expressions in the cerebral cortex and hippocampus of young and aged male rats: antioxidant and anti-apoptotic effects of melatonin**
Keskin-Aktan A., AKBULUT K. G., Abdi S., AKBULUT H.
BIOLOGIA FUTURA, vol.73, no.1, pp.71-85, 2022 (SCI-Expanded)
- VII. **The role of pericytes on the efficacy of bevacizumab in colorectal cancer**
Besler M., Dost F. S., ÇAY ŞENLER F., KIRMIZI B. A., SAVAŞ B., AKBULUT H.
Turkish Journal of Medical Sciences, vol.52, no.5, pp.1543-1550, 2022 (SCI-Expanded)
- VIII. **Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study**
AKARCA U. S., Unsal B., Sezgin O., Yalcin K., Akdogan M., Gonen C., Gunduz F., Ozenirler S., SONSUZ A., DİNÇER D., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1019-1028, 2021 (SCI-Expanded)
- IX. **mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors**
Yekeduz E., Ayasun R., KÖKSOY E. B., UTKAN G., ÜRÜN Y., AKBULUT H.
FUTURE VIROLOGY, vol.16, no.9, pp.583-585, 2021 (SCI-Expanded)
- X. **Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients**
Alkan A., Guc Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., Telli T. A., KESKİN Ö., Arslan C., Bilgin B., et al.
JOURNAL OF MENS HEALTH, vol.17, no.4, pp.128-134, 2021 (SCI-Expanded)
- XI. **A trial-level correlation analysis of progression-free survival as a surrogate for overall survival in the immunotherapy era.**
Yekeduz E., Köksoy E. B., Akbulut H., Utkan G., Urun Y.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15_suppl, pp.18580, 2021 (SCI-Expanded)
- XII. **Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer**
YAZICI O., Dogan M., Ozal G., AKTAŞ S. H., Demirkazık A., UTKAN G., ÇAY ŞENLER F., Icli F., AKBULUT H.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol.24, no.8, pp.1229-1235, 2021 (SCI-Expanded)
- XIII. **A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.**
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., UTKAN G., ÜRÜN Y.

JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)

- XIV. **ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis**
Yekeduz E., KÖKSOY E. B., AKBULUT H., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY, vol.17, no.03, pp.349-357, 2021 (SCI-Expanded)
- XV. **Application of vascular endothelial growth factor at different phases of intestinal ischemia/reperfusion: What are its effects on oxidative stress, inflammation and telomerase activity?**
Korkmaz A., OYAR E. Ö., Yildirim Z., Pampal A., Unlu N. L., AKBULUT H.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, vol.29, no.12, pp.1417-1424, 2020 (SCI-Expanded)
- XVI. **Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study**
Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., ŞENDUR M. A. N., Sezer A., KILIÇKAP S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.267-272, 2020 (SCI-Expanded)
- XVII. **Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study**
YALÇIN Ş., Dane F., Oksuzoglu B., Ozdemir N. Y., Isikdogan A., ÖZKAN M., Demirag G. G., COŞKUN H. Ş., KARABULUT B., EVRENSEL T., et al.
BMC CANCER, vol.20, no.1, 2020 (SCI-Expanded)
- XVIII. **Immune gene therapy of cancer**
AKBULUT H.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.50, pp.1679-1690, 2020 (SCI-Expanded)
- XIX. **Oxidative Stress and Sirtuin2 Changes in Different Parts of the Brain in Aging: Protective Effect of Melatonin**
AKBULUT K. G., Aktan A. K., Abgarmi S. A., AKBULUT H.
ACTA PHYSIOLOGICA, vol.227, pp.91, 2019 (SCI-Expanded)
- XX. **Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study**
ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., ŞENDUR M. A. N., Sezer A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1658-1664, 2019 (SCI-Expanded)
- XXI. **The Role of Tumor Microenvironment in Genomic Instability of Malignant Tumors**
SONUGÜR F. G., AKBULUT H.
FRONTIERS IN GENETICS, vol.10, 2019 (SCI-Expanded)
- XXII. **A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy**
AKBULUT H., ÇÖLERİ CİHAN A., ŞAHİN G., Tang Y., Icli F.
HUMAN GENE THERAPY, vol.30, no.8, pp.999-1007, 2019 (SCI-Expanded)
- XXIII. **Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer**
Gunay F. S. D., KIRMIZI B. A., ENSARİ A., Icli F., AKBULUT H.
CLINICAL COLORECTAL CANCER, vol.18, no.2, 2019 (SCI-Expanded)
- XXIV. **Neuroprotective Effects of Sirt2 Inhibition In Aging**
Aktan A. K., AKBULUT K. G., AKBULUT H.
ACTA PHYSIOLOGICA, vol.225, pp.30, 2018 (SCI-Expanded)
- XXV. **Age-Related Changes in the Oxidative Stress, Apoptosis, SIRT2 and Autophagy in the Cerebral Cortex: Protective Effects of Melatonin**
AKBULUT K. G., Keskin-Aktan A., Abgarmi S. A., AKBULUT H.
ACTA PHYSIOLOGICA, vol.225, pp.37, 2018 (SCI-Expanded)

- XXVI. **Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer**
Kaya D. M., Orturk B., Kubilay P., Onur H., UTKAN G., ÇAY ŞENLER F., Alkan A., Yerlikaya H., KÖKSOY E. B., Karci E., et al.
FUTURE ONCOLOGY, vol.14, no.15, pp.1461-1467, 2018 (SCI-Expanded)
- XXVII. **The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.**
AKBULUT H., Ocal M., Sonugur F. G., Abgarmi S. A., BABAHAN C., Akay B., Arslan U. Y., Artac M., Sendur M. A. N., Demirkazik A.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXVIII. **The effects of melatonin and curcumin on the expression of SIRT2, Bcl-2 and Bax in the hippocampus of adult rats**
Keskin-Aktan A., Akbulut K. G., Yazici-Mutlu C., Sonugür F. G., Ocal M., Akbulut H.
BRAIN RESEARCH BULLETIN, pp.306-310, 2018 (SCI-Expanded)
- XXIX. **The Effects of Curcumin Administration on Hippocampal SIRT2, BCL-2, BAX And BIM Expressions in Young and Aged Rats**
Aktan A. K., AKBULUT K. G., AKBULUT H.
ACTA PHYSIOLOGICA, vol.221, pp.25-26, 2017 (SCI-Expanded)
- XXX. **Significance of tumour-infiltrating lymphocytes (TILs) in gastric carcinomas: Association of PD-L1 and PD-1 expression with prognostic parameters and survival**
Arman A. F., Yasar H. A., Savas B., AKBULUT H., ENSARİ A.
VIRCHOWS ARCHIV, vol.471, 2017 (SCI-Expanded)
- XXXI. **Vaccination in oncology practice and predictors**
Alkan A., Karci E., Yasar A., Tuncay G., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., AKBULUT H., et al.
SUPPORTIVE CARE IN CANCER, vol.25, no.9, pp.2677-2682, 2017 (SCI-Expanded)
- XXXII. **The significance of serum leptin level in patients with early stage nonsmall cell lung cancer**
Karatas F., YALÇIN B., Sahin S., AKBULUT H., UTKAN G., DEMİRKAZIK A., Icli F.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.13, no.2, pp.204-207, 2017 (SCI-Expanded)
- XXXIII. **Aflibercept-related nasal septum perforation**
Alkan A., Yucel L., Mizrak D., AKBULUT H.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, 2017 (SCI-Expanded)
- XXXIV. **A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer**
Aktas S. H., AKBULUT H., Yazici O., Zengin N., Akgun H. N., Ustuner Z., Icli F.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.2, pp.399-406, 2017 (SCI-Expanded)
- XXXV. **Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients**
Alkan A., Yasar A., Karci E., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., ÜRÜN Y., Tuncay G., ERGÜN H., AKBULUT H.
SUPPORTIVE CARE IN CANCER, vol.25, no.1, pp.229-236, 2017 (SCI-Expanded)
- XXXVI. **Prognostic Importance of Bone Marrow Uptake on Baseline F-18-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma**
SOYDAL Ç., KÖKSOY E. B., Yasar A., Turgal E., DOĞANAY ERDOĞAN B., AKBULUT H., KÜÇÜK N. Ö.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol.31, no.10, pp.361-365, 2016 (SCI-Expanded)
- XXXVII. **Medical oncologists' attitudes towards vaccination in oncology practice**
Alkan A., Karci E., Yasar A., Tuncay G., Urun M., Koksoy E. B., Urun Y., Senler F. C., Utkan G., DEMİRKAZIK A., et al.
ANNALS OF ONCOLOGY, vol.27, 2016 (SCI-Expanded)
- XXXVIII. **The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)**
AKBULUT H., Ocal M., Sonugur G., AKAY B. N., BABAHAN C., Abgarmi S. A., DEMİRKAZIK A., Icli F.
ANNALS OF ONCOLOGY, vol.27, 2016 (SCI-Expanded)
- XXXIX. **Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish**

Oncology Group (TOG)

Alkan A., Guc Z. G., ÇAY ŞENLER F., YAVUZŞEN T., Onur H., Dogan M., Karci E., Yasar A., KÖKSOY E. B., TANRIVERDİ Ö., et al.

SUPPORTIVE CARE IN CANCER, vol.24, no.9, pp.3747-3755, 2016 (SCI-Expanded)

- XL. **A novel fluorescence turn-on coumarin-pyrazolone based monomethine probe for biothiol detection**
Babur B., SEFEROĞLU N., Ocal M., SONUGÜR F. G., AKBULUT H., SEFEROĞLU Z.
TETRAHEDRON, no.30, pp.4498-4502, 2016 (SCI-Expanded)
- XLI. **Baculoviral vector loaded mesenchymal stem cells as efficient gene therapy tools for cancer treatment**
Aktas S. H., Akbulut H., Elçin A. E., Parmaksız M., Keskin A. A., Çöleri Cihan A., Elçin Y. M., Icli F.
TURKISH JOURNAL OF BIOLOGY, vol.40, no.5, pp.1121-1128, 2016 (SCI-Expanded)
- XLII. **Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)**
Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., Dogu G. G., Erlep Y., Uslu R., Sevinc A., et al.
BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded)
- XLIII. **The Effect of Melatonin, Curcumin and Salermide on Sirt2 expression Level of Hippocampus in Middle Aged Rats**
AKBULUT K. G., Aktan A. K., Mutlu C. Y., AKBULUT H.
ACTA PHYSIOLOGICA, vol.215, pp.44, 2015 (SCI-Expanded)
- XLIV. **More prognostic factors in early stage breast cancer**
Mizrak D., Ozturk B., Kubilay P., AKBULUT H., Onur H.
BREAST, vol.24, 2015 (SCI-Expanded)
- XLV. **Effect of tumor hormonal and HER2 status on localization of metastases in recurrent breast cancer**
Mizrak D., Onur H., Ozturk B., Kubilay P., AKBULUT H.
BREAST, vol.24, 2015 (SCI-Expanded)
- XLVI. **Effect of HER2 and hormonal status to FDG uptake on PET/CT imaging in recurrent breast cancer**
Mizrak D., Onur H., Ozturk B., Kubilay P., Utkan G., AKBULUT H.
BREAST, vol.24, 2015 (SCI-Expanded)
- XLVII. **Serum levels of CEA and CA 15-3 in different subtypes of recurrent breast cancer**
Mizrak D., Ozturk B., Kubilay P., AKBULUT H., Onur H.
BREAST, vol.24, 2015 (SCI-Expanded)
- XLVIII. **Preoperative systemic therapy for locally advanced breast cancer: single center experience**
Mizrak D., Kubilay P., Ozturk B., Onur H., AKBULUT H.
BREAST, vol.24, 2015 (SCI-Expanded)
- XLIX. **Blood group: is it associated with tumor biology in breast cancer?**
Mizrak D., Kubilay P., Ozturk B., AKBULUT H., Onur H.
BREAST, vol.24, 2015 (SCI-Expanded)
- L. **The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer**
ÜRÜN Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., Oztuna D., Şenler F., DEMİRKAZIK A., İçli F.
Experimental Oncology, vol.37, no.1, pp.53-57, 2015 (SCI-Expanded)
- LI. **Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)**
Aykan N. F., YALÇIN Ş., Turhal N. S., Ozdogan M., Demir G., ÖZKAN M., YAREN A., Camci C., AKBULUT H., Artac M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.26, no.2, pp.145-153, 2015 (SCI-Expanded)
- LII. **The role of melatonin, sirtuin2 and FoxO1 transcription factor in the aging process of colon in male rats**
AKBULUT K. G., Aktas S. H., AKBULUT H.
BIogerontology, vol.16, no.1, pp.99-108, 2015 (SCI-Expanded)
- LIII. **Fighting Against Cigarette Smoking Among Medical Students: A Success Story**

- Icli F., ODABAŞ D., Gonullu U., Sunguroglu K., Akdur R., AKBULUT H., Ozkan A., Olmez S., GÖNÜLLÜ İ., İBİŞ E.
JOURNAL OF CANCER EDUCATION, vol.29, no.3, pp.458-462, 2014 (SCI-Expanded)
- LIV. **The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey**
Dogan M., DEMİRKAZIK A., Tukun A., SAK S., CEYHAN K., Yalcin B., AKBULUT H., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.1, pp.1-10, 2014 (SCI-Expanded)
- LV. **Angiogenesis and anti-angiogenic treatments in colorectal cancer Kolorektal kanserde anjiyogenez ve anti-anjiyogenik tedaviler**
Aktaş S. H., AKBULUT H.
Türk Onkoloji Dergisi, vol.29, no.2, pp.67-79, 2014 (SCI-Expanded)
- LVI. **WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133(+)/CD44(+) prostate cancer stem cell spheroids**
Goksel G., Bilir A., Uslu R., AKBULUT H., Guven U., ÖKTEM G.
JOURNAL OF BUON, vol.19, no.1, pp.207-214, 2014 (SCI-Expanded)
- LVII. **Designing gene therapy vectors targeting tumor cell endothelium Kanserde damar endoteline yönelik gen tedavisi ajanları{dotless} geliştirilmesi**
Özkal Baydin P., AKBULUT H.
Türk Onkoloji Dergisi, vol.28, no.4, pp.179-186, 2013 (SCI-Expanded)
- LVIII. **Melatonin Delays Brain Aging by Decreasing the Nitric Oxide Level**
Akbulut K. G., Guney S., Cetin F., Akgun H. N., Aktas S. H., AKBULUT H.
NEUROPHYSIOLOGY, vol.45, no.3, pp.187-192, 2013 (SCI-Expanded)
- LIX. **Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members**
ÜRÜN Y., AKBULUT H., DEMİRKAZIK A., Senler F. C., Utkan G., Onur H., Icli F.
JOURNAL OF BUON, vol.18, no.2, pp.511-515, 2013 (SCI-Expanded)
- LX. **TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases**
Deisseroth A., Tang Y., Zhang L., AKBULUT H., Habib N.
CANCER GENE THERAPY, vol.20, no.2, pp.65-69, 2013 (SCI-Expanded)
- LXI. **Smoking Habits of Relatives of Patients with Cancer: Cancer Diagnosis in the Family is an Important Teachable Moment for Smoking Cessation**
HAYRAN K. M., Kilickap S., ELKIRAN E. T., AKBULUT H., Abali H., YÜCE D., Kilic D., Turhal S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.1, pp.475-479, 2013 (SCI-Expanded)
- LXII. **Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature**
Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., AKBULUT H., Zengin N., Alkis N., Icli F.
MEDICAL ONCOLOGY, vol.29, no.3, pp.2021-2026, 2012 (SCI-Expanded)
- LXIII. **ABO and Rh blood groups frequency in women with HER2 positive breast cancer**
ÜRÜN Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., Kocer M., DOĞAN İ., Senler F. C., Yalcin B., et al.
JOURNAL OF BUON, vol.17, no.3, pp.457-460, 2012 (SCI-Expanded)
- LXIV. **Primary extranodal non-Hodgkin's lymphoma presenting as painful gingival swelling**
ÜRÜN Y., Can F., BARIŞ E., AKBULUT H., UTKAN G., Icli F.
Experimental Oncology, vol.34, no.2, pp.134-135, 2012 (SCI-Expanded)
- LXV. **Melatonin decreases apoptosis in gastric mucosa during aging**
AKBULUT K. G., AKBULUT H., Akgun N., Gonul B.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, vol.24, no.1, pp.15-20, 2012 (SCI-Expanded)
- LXVI. **Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group**
ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., Kaplan M. A., Arslan U. Y., ÖZDEMİR F., Oztuna D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.8, pp.4129-4131, 2012 (SCI-Expanded)
- LXVII. **ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma**

ÜRÜN Y., Ozdemir N. Y., UTKAN G., AKBULUT H., SAVAŞ B., Oksuzoglu B., Oztuna D., DOĞAN İ., YALÇIN B., ÇAY ŞENLER F., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.12, pp.6097-6100, 2012 (SCI-Expanded)

LXVIII. Characteristics of Oropharyngeal Candida and Bacterial Colonization in Cancer Patients

ÇAY ŞENLER F., Cakmakci S., Akan O. A., DEMİRKAZIK A., AKBULUT H., Icli F.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.2, pp.113-119, 2012 (SCI-Expanded)

LXIX. Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients

Dogan M., KARABULUT H. G., Tukun A., DEMİRKAZIK A., UTKAN G., Yalcin B., Dincol D., AKBULUT H., Icli F.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.4, pp.1553-1556, 2012 (SCI-Expanded)

LXX. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: A tentative relationship between drug type and tumor cell type response

Aktas S. H., AKBULUT H., Akgun N., Icli F.

CANCER BIOMARKERS, vol.12, no.3, pp.135-140, 2012 (SCI-Expanded)

LXXI. The effect of age and Helicobacter pylori infection on gastric epithelial cell kinetics

Coban S., Soykan I., TÖRÜNER M., AKBULUT H., Atli T., ENSARİ A.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.35, no.10, pp.661-665, 2011 (SCI-Expanded)

LXXII. Angiosarcoma related to immunosuppressive therapy 8 years after renal transplantation

ÜRÜN Y., DOĞAN İ., KİREMİTÇİ S., AKBULUT H., Icli F.

ANNALS OF TRANSPLANTATION, vol.16, no.4, pp.138-140, 2011 (SCI-Expanded)

LXXIII. The role of Phe329 in binding of cationic triarylmethane dyes to human butyrylcholinesterase

BİBEROĞLU K., TACAL Ö., AKBULUT H.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol.511, no.1-2, pp.64-68, 2011 (SCI-Expanded)

LXXIV. Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., Bektas M., Arat M., AKBULUT H., DOĞANAY ERDOĞAN B., et al.

JOURNAL OF MEDICAL VIROLOGY, vol.83, no.6, pp.974-980, 2011 (SCI-Expanded)

LXXV. Golgi protein 73 (gp73) is a useful tumor marker in patients with colon cancer.

Ozal G., AKBULUT H., Akgun N., Cipe G., Icli F.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

LXXVI. The relationship between common EGFR, b-raf, k-ras mutations, and prognosis in advanced-stage NSCLC with response to the treatment

Dogan M., Demirkazik A., Tukun A., AKBULUT H., SAK S., Ceyhan K., Yalcin B., Icli F.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

LXXVII. The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.

Yazici O., AKBULUT H., Akgun N., Utkan G., Yalcin B., Icli F.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

LXXVIII. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)

AKBULUT H., Altundag M. K., Saip P., COŞKUN H. Ş., Camci C., Ozkan M., Paydas S., Zengin N., Alco G., Aliustaoglu M., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

LXXIX. The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.

Turhal N. S., Kilickap S., Yalcin S., Sezgin C., Yamac D., AKBULUT H., Ozyilkan O., Ozdemir F., Cabuk D., Sevinc A.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

LXXX. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10

years follow-up)

Icli F., AKBULUT H., Onur H., Yalcin B., DEMİRKAZIK A., ÇAY ŞENLER F.
BREAST, vol.20, no.2, pp.155-157, 2011 (SCI-Expanded)

- LXXXI. Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish oncology group"**

Icli F., AKBULUT H., Yalcin B., Ozdemir F., Isikdogan A., HAYRAN K. M., Unsal D., Coskun S., Buyukcelik A., Yamac D.
MEDICAL ONCOLOGY, vol.28, no.1, pp.112-120, 2011 (SCI-Expanded)

- LXXXII. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study-A Turkish Oncology Group trial**

Aykan N., Demir G., Disci R., Yalcin S., Turhal N. S., Ozdogan M., Ozkan M., Yaren A., Camel C., AKBULUT H.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (SCI-Expanded)

- LXXXIII. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells**

AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Deisseroth A.
GENE THERAPY, vol.17, no.11, pp.1333-1340, 2010 (SCI-Expanded)

- LXXXIV. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP**

Dincol D., Buyukcelik A., Dogan M., AKBULUT H., Samur M., DEMİRKAZIK A., ÇAY ŞENLER F., Onur H., Icli F.
MEDICAL ONCOLOGY, vol.27, no.3, pp.942-945, 2010 (SCI-Expanded)

- LXXXV. IgA lambda oligoclonal gammopathy in multiple myeloma**

Tek I., Mizrak D., Utkan G., TOPRAK S. K., Tutkak H., Buyukcelik A., Yalcin B., AKBULUT H., Icli F.
TURKISH JOURNAL OF HEMATOLOGY, vol.27, no.2, pp.126-127, 2010 (SCI-Expanded)

- LXXXVI. The effects of chemotherapeutic drugs on VEGF secretion of solid tumours**

AKBULUT H., Aktas S. H., Ozal G., Zengin N., Akgun N., Ustuner Z., Ozdemir N., Yazici O., Icli F.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)

- LXXXVII. The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis**

DEMİRKAZIK A., Asik M., Yalcin B., Dogan M., Buyukcelik A., Sencan O., UTKAN G., AKBULUT H., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.1, pp.14-19, 2010 (SCI-Expanded)

- LXXXVIII. Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors**

Han T. H., Tang Y., Park Y. H., Maynard J., Li P., AKBULUT H., Petersen L., Deisseroth A.
BONE MARROW TRANSPLANTATION, vol.45, no.3, pp.550-557, 2010 (SCI-Expanded)

- LXXXIX. Modification and implementation of NCCN guidelines on colon cancer in the Middle East and North Africa region.**

Içli F., AKBULUT H., Bazarbashi S., Kuzu M. A., Mallath M. K., Rasul K. I., Strong S., Syed A. A., ZORLU A. F., Engstrom P. F., et al.
Journal of the National Comprehensive Cancer Network : JNCCN, vol.8 Suppl 3, 2010 (SCI-Expanded)

- XC. The role of melatonin on gastric mucosal cell proliferation and telomerase activity in ageing**

AKBULUT K. G., Gonul B., AKBULUT H.
JOURNAL OF PINEAL RESEARCH, vol.47, no.4, pp.308-312, 2009 (SCI-Expanded)

- XCI. Vector vaccination and vector targeted chemotherapy in solid tumors**

AKBULUT H., Tang Y., Deisseroth A.
Journal of B.U.ON., vol.14, no.SUPPL.1, 2009 (SCI-Expanded)

- XCII. COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY**

Tatar M., AKBULUT H.
VALUE IN HEALTH, vol.12, no.7, 2009 (SCI-Expanded)

- XCIII. Vector vaccination and vector targeted chemotherapy in solid tumors**

AKBULUT H., Tang Y., Deisseroth A.

JOURNAL OF BUON, vol.14, 2009 (SCI-Expanded)

- XCIV. **Mutation profile of Turkish gastrointestinal stromal tumor cases: a multicenter study**
Kaygusuz G., Suner S., Karatayli E., Bulbul D. G., Ozoran Y., AKBULUT H., Molinas M. N., KUZU I.
VIRCHOWS ARCHIV, vol.455, pp.57, 2009 (SCI-Expanded)
- XCV. **Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses**
ERSOY P. E., AKBULUT H., Moray G.
SURGERY TODAY, vol.39, no.1, pp.38-43, 2009 (SCI-Expanded)
- XCVI. **Breast cancer with diabetes insipidus**
DOĞAN M. K., Karakilic E., Oz I., ZORLU A. F., AKBULUT H.
Experimental Oncology, vol.30, no.4, pp.324-326, 2008 (SCI-Expanded)
- XCVII. **Exogenous melatonin decreases age-induced lipid peroxidation in the brain**
AKBULUT K. G., Gonul B., AKBULUT H.
BRAIN RESEARCH, vol.1238, pp.31-35, 2008 (SCI-Expanded)
- XCVIII. **Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells**
AKBULUT H., Tang Y., AKBULUT K. G., Albert J. M., Deisseroth A.
MOLECULAR THERAPY, vol.16, no.10, pp.1753-1760, 2008 (SCI-Expanded)
- XCIX. **Combination of vaccine with targeted chemotherapy reduced levels of CSC like (CD44(+)/CD24(-) hematopoietic lineage negative {LIN-}) cells and improves outcome of cancer treatment**
AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Deisseroth A. B.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- C. **Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas**
Yaman E., Yalcin B., Utkan G., AKBULUT H., Isikdogan A., Sencan O., Buyukcelik A., Pamir A., DEMİRKAZIK A., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.18, no.2, pp.79-84, 2008 (SCI-Expanded)
- CI. **The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.**
Sencan O., Buyukcelik A., Yalcin B., Boruban M. C., AKBULUT H., DEMİRKAZIK A., Senler F., Onur H., Icli F.
European journal of cancer care, vol.17, no.1, pp.26-32, 2008 (SCI-Expanded)
- CII. **Alveolar adenoma of the lung**
SAK S., KÖSEOĞLU R. D., Demirag F., AKBULUT H., Gungor A.
APMIS, vol.115, no.12, pp.1443-1449, 2007 (SCI-Expanded)
- CIII. **Opinions of the Turkish population on cancer and being informed for the diagnosis of cancer: An opinion survey**
Yalcin B., Yalcin S., Buyukcelik A., Sencan O., Dogan M., Turk M., Ozdemir F., Isikdogan A., Er O., AKBULUT H., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- CIV. **Symptoms or signs due to different chemotherapeutics and their relationship with serum cytokines/VEGF levels in patients with cancer**
DEMİRKAZIK A., Yilmaz H., AKBULUT H., Yalcin B., Icli F.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- CV. **Donor lymphocyte infusions from Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost (VPP) vaccinated allodonors decrease tumor cell growth post allograft**
Deisseroth A. B., Tang Y., AKBULUT H., Maynard J., Petersen L.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- CVI. **Low molecular weight heparin (LMWH) increases the efficacy of cisplatin plus gemcitabine combination in advanced pancreatic cancer**
Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., DEMİRKAZIK A., Onur H., Cay F., Buyukcelik A.
JOURNAL OF SURGICAL ONCOLOGY, vol.95, no.6, pp.507-512, 2007 (SCI-Expanded)
- CVII. **Vaccine for Cancer and Infectious Diseases**
Deisseroth A. B., Tang Y., AKBULUT H., Maynard J., Pedersen L.
JOURNAL OF IMMUNOLOGY, vol.178, 2007 (SCI-Expanded)

- CVIII. Hepatitis B and C seroprevalence in cancer patients: A case control study** **Kanserli hastalarda hepatit B ve C sikliğı: Vaka kontrol çalışması**
 Utkan G., AZAP A., Muallaoglu S., Tokluoglu S., Durnali A. G., Arslan Ü. Y., Koçer M., Çelenkoğlu G., AKBULUT H., Alkış N.
 UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.16, no.3, pp.103-107, 2006 (SCI-Expanded)
- CIX. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study**
 Dogan M., Demirkazik A., Konuk N., Yalcin B., Buyukcelik A., Utkan G., Tek I., Akbulut H., Sencan O., Icli F.
 INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol.21, no.4, pp.206-210, 2006 (SCI-Expanded)
- CX. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer**
 Tang Y., AKBULUT H., Maynard J., Petersen L., Fang X., Zhang W., Xia X., Koziol J., Linton P., Deisseroth A.
 JOURNAL OF IMMUNOLOGY, vol.177, no.8, pp.5697-5707, 2006 (SCI-Expanded)
- CXI. Thrombosis of the pulmonary artery in a patient with mucinous adenocarcinoma**
 Buyukcelik A., Yalcin B., Utkan G., Icli F., Sanlidilek U., AKBULUT H.
 MEDICAL SCIENCE MONITOR, vol.12, no.9, 2006 (SCI-Expanded)
- CXII. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.**
 Utkan G., Bueyuekcelik A., Yalcin B., AKBULUT H., DEMİRKAZIK A., Dincol D., Onur H., Goeren D., Mousa U., Senler F., et al.
 Lung cancer (Amsterdam, Netherlands), vol.53, no.3, pp.367-74, 2006 (SCI-Expanded)
- CXIII. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer**
 AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Zhang L., Deisseroth A.
 MOLECULAR CANCER THERAPEUTICS, vol.5, no.8, pp.1975-1985, 2006 (SCI-Expanded)
- CXIV. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy**
 Liu Y., Ye T., Maynard J., AKBULUT H., Deisseroth A.
 CANCER GENE THERAPY, vol.13, no.4, pp.346-356, 2006 (SCI-Expanded)
- CXV. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions**
 Yasa M., Bektas A., Yukselen V., AKBULUT H., Camci C., Ormeci N.
 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.59, no.9, pp.1029-1033, 2005 (SCI-Expanded)
- CXVI. Expression of P53 protein and DNA flow cytometry in gastric adenocarcinoma: Implications in patients treated with adjuvant etoposide, adriamycin and cisplatin**
 Buyukcelik A., Onur H., AKBULUT H., Yalcin B., ENSARİ A., Utkan G., Onal B., Icli F.
 TUMORI JOURNAL, vol.91, no.4, pp.302-308, 2005 (SCI-Expanded)
- CXVII. Lymphoscintigraphy in pregnant patients with breast cancer: is it really safe?**
 Tek I., Buyukcelik A., Yalcin B., AKBULUT H.
 ANNALS OF ONCOLOGY, vol.16, no.4, pp.674, 2005 (SCI-Expanded)
- CXVIII. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.**
 Icli F., AKBULUT H., Uner A., Yalcin B., Baltali E., Altinbas M., Coskun S., Komurcu S., Erkisi M., DEMİRKAZIK A., et al.
 British journal of cancer, vol.92, no.4, pp.639-44, 2005 (SCI-Expanded)
- CXIX. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas**
 Yalcin B., Pamir A., Buyukcelik A., Utkan G., Abulut H., Demirkazik A., Icli F.
 EXPERIMENTAL ONCOLOGY, vol.26, no.4, pp.320-325, 2004 (SCI-Expanded)
- CXX. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms**
 AKBULUT H., Tang Y., Maynard J., Zhang L., Pizzorno G., Deisseroth A.
 CLINICAL CANCER RESEARCH, vol.10, no.22, pp.7738-7746, 2004 (SCI-Expanded)

- CXXI. **Overdose of lomustine: Report of two cases**
Buyukcelik A., Akbulut H., Yalcin B., Ozdemir F., Icli F.
TUMORI JOURNAL, vol.90, no.6, pp.628-629, 2004 (SCI-Expanded)
- CXXII. **Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens**
Tang Y., Zhang L., Yuan J., AKBULUT H., Maynard J., Linton P., Deisseroth A.
BLOOD, vol.104, no.9, pp.2704-2713, 2004 (SCI-Expanded)
- CXXIII. **Serum vascular endothelial growth factor levels in patients with nonsmall, cell lung cancer**
DEMİRKAZIK A., AKBULUT H., Ulger A., Arican A., Ozer I., Acikgoz N., Icli F.
ANNALS OF SAUDI MEDICINE, vol.24, no.6, pp.473-475, 2004 (SCI-Expanded)
- CXXIV. **The effects of chronomodulated therapy with 5-fluorouracil (5-Fu) and folinic acid (Fa) on the toxicity and quality of life in patients with advanced gastric cancer**
Yalcin B., AKBULUT H., Buyukcelik A., Sencan O., Demirkazik A., Onur H., Senler F., Dincol D., Icli F.
BIOLOGICAL RHYTHM RESEARCH, vol.35, no.4-5, pp.259-268, 2004 (SCI-Expanded)
- CXXV. **Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma**
AKBULUT H., Icli F., Yalcin B., DEMİRKAZIK A., Onur H., Buyukcelik A., Utkan G.
EXPERIMENTAL ONCOLOGY, vol.26, no.2, pp.149-152, 2004 (SCI-Expanded)
- CXXVI. **Thromboembolism in patients with cancer**
Büyükcelik A., AKBULUT H.
Turkish Journal of Haematology, vol.21, no.1, pp.7-11, 2004 (SCI-Expanded)
- CXXVII. **Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies**
Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., Arslan O., Ozcan M., Turkyilmaz A., Bozdayi M., et al.
JOURNAL OF VIRAL HEPATITIS, vol.11, no.2, pp.141-147, 2004 (SCI-Expanded)
- CXXVIII. **A new schedule of mitomycin-C and vinorelbine combination in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes: A phase II study**
Yalcin B., ÜNER A., AKBULUT H., Icli F., Buyukcelik A., Isikdogan A., Dincol D., DEMİRKAZIK A., Onur H., Bozcuk H.
ANNALS OF ONCOLOGY, vol.15, pp.42, 2004 (SCI-Expanded)
- CXXIX. **The prognostic Importance of Venous Thromboembolism (VT) in cancer patients and its relationship with the levels of factor VIII and Vascular Endothelial Growth Factor (VEGF)**
DEMİRKAZIK A., Dogan M., Konuk N., AKBULUT H., Yalcin B., Buyukcelik A., Tek I., UTKAN G., Onur H., Icli F.
ANNALS OF ONCOLOGY, vol.15, pp.151, 2004 (SCI-Expanded)
- CXXX. **An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells**
Zhang L., Tang Y., AKBULUT H., Zelterman D., Linton P., Deisseroth A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol.100, no.25, pp.15101-15106, 2003 (SCI-Expanded)
- CXXXI. **Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon**
AKBULUT H., Zhang L., Tang Y., Deisseroth A.
CANCER GENE THERAPY, vol.10, no.5, pp.388-395, 2003 (SCI-Expanded)
- CXXXII. **Daily variations of plasma malondialdehyde levels in patients with early breast cancer**
Akbulut H., Akbulut K., Icli F., Buyukcelik A.
CANCER DETECTION AND PREVENTION, vol.27, no.2, pp.122-126, 2003 (SCI-Expanded)
- CXXXIII. **Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.**
Akbulut H., ALTUNTAŞ F., Akbulut K., Ozturk G., Cindoruk M., Unal E., Icli F.
Cytokine, vol.20, no.4, pp.184-90, 2002 (SCI-Expanded)
- CXXXIV. **Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for**

breast cancer and melanoma

Zhang L., AKBULUT H., Tang Y., Peng X., Pizzorno G., Sapi E., Manegold S., Deisseroth A.
MOLECULAR THERAPY, vol.6, no.3, pp.386-393, 2002 (SCI-Expanded)

- CXXXV. **Effect of granulocyte-macrophage colony-stimulating factor on hepatic regeneration after 70% hepatectomy in normal and cirrhotic rats**
EROĞLU A. H., DEMİRCİ S., AKBULUT H., Sever N., DEMİRER S., ÜNAL A. E.
HPB, vol.4, no.2, pp.67-73, 2002 (SCI-Expanded)
- CXXXVI. **Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma**
Emri S., AKBULUT H., Zorlu F., Dincol D., Akay H., Gungen Y., Icli F.
LUNG CANCER, vol.33, no.2-3, pp.109-114, 2001 (SCI-Expanded)
- CXXXVII. **A randomized trial of four cycles of adjuvant AC (adriamycin plus cyclophosphamide) +/- two cycles of EP (etoposide plus cisplatin) in node positive patients with breast cancer**
Icli F., AKBULUT H., Dincol D., Onur H., DEMİRKAZIK A., Cam R., Cay F., Demirci S., Uner A., Ereku S.
ANNALS OF ONCOLOGY, vol.12, no.7, pp.1011-1013, 2001 (SCI-Expanded)
- CXXXVIII. **The effects of melatonin on humoral immune responses of young and aged rats**
Akbulut K., Gonul B., Akbulut H.
IMMUNOLOGICAL INVESTIGATIONS, vol.30, no.1, pp.17-20, 2001 (SCI-Expanded)
- CXXXIX. **Overdosage of pamidronate in a patient with renal cell carcinoma**
AKBULUT H., Icli F.
MEDICAL ONCOLOGY, vol.17, no.4, pp.340-341, 2000 (SCI-Expanded)
- CXL. **Diurnal variations of serum GM-CSF levels**
Dincol D., Akbulut H., Buyukcelik A., Icli F.
CYTOKINE, vol.12, no.7, pp.1151-1155, 2000 (SCI-Expanded)
- CXLI. **Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma**
Dincol D., Samur M., Pamir A., Sencan O., Akbulut H., Yalcin B., Onur H., Demirkazik A., Senler F., Icli F.
CANCER, vol.88, no.9, pp.2033-2036, 2000 (SCI-Expanded)
- CXLII. **Comparison of 5-fluorouracil-folinic acid and etoposide-doxorubicin-cisplatin chemotherapies in patients with advanced gastric carcinoma: A prospective randomized crossover study, interim analysis.**
Sencan O., DEMİRKAZIK A., AKBULUT H., Yalcin B., Icli F.
ANNALS OF ONCOLOGY, vol.11, pp.70-71, 2000 (SCI-Expanded)
- CXLIII. **The efficacy of irinotecan, cisplatin and dacarbazine combination in patients with metastatic colorectal cancer resistant to 5-fluorouracil.**
AKBULUT H., Icli F., DEMİRKAZIK A., Yalcin B., Buyukcelik A., Cay F.
ANNALS OF ONCOLOGY, vol.11, pp.46, 2000 (SCI-Expanded)
- CXLIV. **Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin's lymphomas in Turkey**
Arıcan A., Dincol D., Akbulut H., Onur H., DEMİRKAZIK A., Cay F., Icli F.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.6, pp.587-592, 1999 (SCI-Expanded)
- CXLV. **Serum "Vascular Endothelial Growth Factor" (VEGF) levels in patients with non-small cell lung cancer (NSCLC)**
Demirkazik A., Ozer I., Akbulut H., Arıcan A., Kulah E., Acikgoz N., Icli F.
EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)
- CXLVI. **Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer**
Eroglu A., Demirci S., Ayyildiz A., Kocaoglu H., Akbulut H., Akgul H., ELHAN A. H.
BRITISH JOURNAL OF CANCER, vol.80, no.10, pp.1630-1634, 1999 (SCI-Expanded)

- CXLVII. Differential effects of pharmacological doses of melatonin on malondialdehyde and glutathione levels in young and old rats**
Akbulut K, Gonul B, Akbulut H.
GERONTOLOGY, vol.45, no.2, pp.67-71, 1999 (SCI-Expanded)
- CXLVIII. The effect of two different doses of oral clodronate on pain in patients with bone metastases**
Arıcan A, İcli F, AKBULUT H., Çakır M., Sencan O., Samur M., Açıkgöz N., DEMİRKAZIK A.
MEDICAL ONCOLOGY, vol.16, no.3, pp.204-210, 1999 (SCI-Expanded)
- CXLIX. Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil**
İcli F., Arıcan A., Cay F., AKBULUT H., Dincol D., Karaoguz H., DEMİRKAZIK A.
ONCOLOGY, vol.56, no.4, pp.297-300, 1999 (SCI-Expanded)
- CL. The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer**
Akbulut H., İcli F., Buyukcelik A., Akbulut K., Demirci S.
JOURNAL OF PINEAL RESEARCH, vol.26, no.1, pp.1-8, 1999 (SCI-Expanded)
- CLI. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma**
İcli F., ÇELİK İ., Aykan F., Uner A., DEMİRKAZIK A., Ozet A., Ozguroglu M., TAŞ F., AKBULUT H., Fırat D.
CANCER, vol.83, no.12, pp.2475-2480, 1998 (SCI-Expanded)
- CLII. Prognostic factors in patients with recurrent breast cancer following mastectomy**
İcli F., Cay F., Dincol D., Karaoguz H., Demirkazik A., Akbulut H.
EUROPEAN JOURNAL OF CANCER, vol.34, 1998 (SCI-Expanded)
- CLIII. The effect of two different doses of oral clodronate on pain in patients with bone metastases**
Ancan A., İcli F., Akbulut H., Cakr M., Sencan O., Samur M., Ackgoz N., Demirkazik A.
EUROPEAN JOURNAL OF CANCER, vol.34, 1998 (SCI-Expanded)
- CLIV. A comparison of imipenem monotherapy versus cefoperazone/sulbactam plus amikacin combination treatment in febrile neutropenic cancer patients**
Dincol D., Arıcan A., Aydin F., Samur M., Willke A., AKBULUT H., Pamir A., Cay F., İcli F.
CANCER JOURNAL - FRANCE, vol.11, no.2, pp.89-93, 1998 (SCI-Expanded)
- CLV. Cisplatin and epirubicin induction chemotherapy followed by chemoradiotherapy in limited stage small cell lung cancer (LS-SCLC)**
Cay F., Onat H., Saip P., Kars A., DEMİRKAZIK A., AKBULUT H., Koca S., Akyol F., Aktan G., Fırat D.
ANNALS OF ONCOLOGY, vol.9, pp.104, 1998 (SCI-Expanded)
- CLVI. Surgical resection followed by adjuvant chemotherapy in small cell lung cancer with limited disease**
Arıcan A., Dincol D., AKBULUT H., Cay F., İcli F., Karaoguz H., DEMİRKAZIK A.
ANNALS OF ONCOLOGY, vol.9, pp.105-106, 1998 (SCI-Expanded)
- CLVII. Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy**
AYDİN F., DEMİRKAZIK A., İcli F., AKBULUT H., Samur M.
Journal of Chemotherapy, vol.10, no.5, pp.394-398, 1998 (SCI-Expanded)
- CLVIII. Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer**
Arıcan A., Dincol D., Samur M., Demirkazık A., Sencan O., Akbulut H., Karaoguz H., Cay F., İcli F.
EUROPEAN JOURNAL OF CANCER, vol.33, 1997 (SCI-Expanded)
- CLIX. Comparative study of imipenem versus sulperazone plus amikacin in febrile neutropenia**
Dincol D., Arıcan A., Aydin F., Samur M., Willke A., Akbulut H., Pamir A., Cay F., İcli F.
EUROPEAN JOURNAL OF CANCER, vol.33, pp.253, 1997 (SCI-Expanded)
- CLX. Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)+/-bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey**
Dincol D., AKBULUT H., İcli F., Samur M., Karaoguz H., DEMİRKAZIK A., Cay F.

ONCOLOGY, vol.54, no.5, pp.376-379, 1997 (SCI-Expanded)

- CLXI. **Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease - A Turkish experience**

Akbulut H., Soykan I., Yakaryilmaz F., Icli F., Aksoy F., Haznedaroglu S., Yildirim S.

CANCER, vol.80, no.1, pp.8-14, 1997 (SCI-Expanded)

- CLXII. **Malondialdehyde and glutathione in rat gastric mucosa and effects of exogenous melatonin**

Akbulut H., Akbulut K., Gonul B.

DIGESTIVE DISEASES AND SCIENCES, vol.42, no.7, pp.1381-1382, 1997 (SCI-Expanded)

- CLXIII. **Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric**

Icli F., Karaoguz H., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F.

JOURNAL OF SURGICAL ONCOLOGY, vol.64, no.4, pp.318-323, 1997 (SCI-Expanded)

- CLXIV. **Two dose levels of ifosfamide in malignant mesothelioma**

Icli F., Karaoguz H., Hasturk S., Kurt B., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F., Akyar S.

LUNG CANCER, vol.15, no.2, pp.207-213, 1996 (SCI-Expanded)

- CLXV. **Serum and tissue zinc concentrations in patients with duodenal ulcers DUODENUM ULSERLI HASTALARDA SERUM VE DOKU ÇİNKO DÜZEYLERİ**

Soykan I., AKBULUT H., YILDIRIM İ. E., Haznedaroglu S.

Turkish Journal of Gastroenterology, vol.7, no.1, pp.53-56, 1996 (SCI-Expanded)

- CLXVI. **Results of the cyclophosphamide, adriamycine, vincristine, prednisolon (CHOP) +/- bleomycine treatment and evaluation of prognostic factors in aggressive lymphomas**

Dincol D., Icli F., Akbulut H., Samur M., Karaoguz H., Demirkazik A., Cay F.

EUROPEAN JOURNAL OF CANCER, vol.31A, pp.784, 1995 (SCI-Expanded)

- CLXVII. **MESNA IFOSFAMIDE, MITOXANTRONE, ETOPOSIDE, BLEOMYCIN, VINCRISTINE, PREDNISONE (MINE-BOP) COMBINATION CHEMOTHERAPY IN THE TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA**

DINCOL D., ICLI F., KARAOGUZ H., CAY F., ARICAN A., DEMİRKAZIK A., AKBULUT H.

ACTA ONCOLOGICA, vol.34, no.7, pp.937-940, 1995 (SCI-Expanded)

Articles Published in Other Journals

- I. **The role of SIRT2 inhibition on the aging process of brain in male rats.**

Akbulut K. G., Keskin-Aktan A., Abgarmi S. A., Akbulut H.

Aging brain, vol.4, pp.100087, 2023 (Peer-Reviewed Journal)

- II. **Factors affecting survival in locally advanced rectal cancer - Single center experience**

Yasar H. A., Örüncü M. B., UTKAN G., Akbulut H.

Akademik Gastroenteroloji Dergisi, vol.22, no.2, pp.71-76, 2023 (Peer-Reviewed Journal)

- III. **The relation between gastric cancer and ABO blood groups: multicenter, observational, case-control study**

Yasar H. A., UTKAN G., Ozdemir N., oksuzoglu b., DEDE İ., ÜRÜN Y., Akbulut H.

Akademik Gastroenteroloji Dergisi, vol.22, no.2, pp.67-70, 2023 (Peer-Reviewed Journal)

- IV. **Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study**

Yekeduz E., DOĞAN İ., Kaya D. M., ÖZGÜR İ., UTKAN G., VATANSEVER S., DEMİRCİ S., AKBULUT H., ÜRÜN Y.

JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.4, pp.870-879, 2022 (ESCI)

- V. **Predictive Factor for Lymph Node Metastasis in Non-Metastatic Colorectal Adenocarcinomas**

Karci E., Ürün Y., Köksoy E. B., Yekedüz E., Utkan G., Akbulut H., Uçar G., Bilgin B., Arslan Ç., Alkan A., et al.

Eurasian Journal of Medical Investigation, vol.6, no.3, pp.279-283, 2022 (Peer-Reviewed Journal)

- VI. **P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH**

MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS

Seval G. C., Kircali E., Koyun D., Karakaya B., Yilmaz H., Yavuz G., Akbulut H., Toprak S. K., Topcuoglu P., Arslan O., et al.

HemaSphere, vol.6, pp.26, 2022 (Scopus)

VII. Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma

Yekedüz E., AKBULUT H., UTKAN G., ÜRÜN Y.

CUREUS JOURNAL OF MEDICAL SCIENCE, vol.14, no.4, 2022 (ESCI)

VIII. Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience

Yekedüz E., Köksoy E. B., Şenler F., Akbulut H., Demirkazık A., Ürün Y., Utkan G.

Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.75, no.1, pp.103-106, 2022 (Peer-Reviewed Journal)

IX. Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.

YEKEDÜZ E., DOĞAN İ., DURU BİRGİ S., KESKİN M., KARAMAN Ş., UTKAN G., KARABULUT S., BAYAR S., AKBULUT H., DEMİRCİ S., et al.

Euroasian journal of hepato-gastroenterology, vol.11, no.2, pp.51-58, 2021 (Peer-Reviewed Journal)

X. Seasonal influenza and pneumococcal vaccination rates among patients with cancer in covid-19 pandemic: A cross-sectional study

Yekedüz E., KÖKSOY E. B., YAZGAN S. C., AKBİYİK İ., BALLI S., Kavak E. E., KALACI E., DURSUN B., Kubilay Tolunay P., Gürbüz M., et al.

Journal of Oncological Science, vol.7, no.2, pp.64-70, 2021 (Scopus)

XI. Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination

Sümbül A. T., YALÇIN S. S., ÖZET A., ÜNAL S., DİZDAR Ö., AKBULUT H., KARAOĞLU A., Karadurmuş N., ŞENDUR M. A. N., Çilbir E., et al.

Journal of Oncological Science, vol.7, no.1, pp.1-6, 2021 (Scopus)

XII. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

Jazieh A. R., AKBULUT H., Curigliano G., Rogado A., Alsharm A. A., Razis E. D., Mula-Hussain L., Errihani H., Khattak A., De Guzman R. B., et al.

JCO GLOBAL ONCOLOGY, vol.6, pp.1428-1438, 2020 (ESCI)

XIII. The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients

ALKAN A., ÜRÜN Y., UTKAN G., AKBULUT H., TUNCAY G., ARAS S., VARLI M.

Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)

XIV. The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients.

ALKAN A., ÖZTORUN H. S., KARCI E., ÜRÜN Y., TUNCAY G., YAŞAR H. A., ÇINAR E., ARAS S., VARLI M., UTKAN G., et al.

Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)

XV. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome

Keskin H., Cadirci K., Demirkazık A., Akbulut H., Yalçın B.

Biomarkers in Cancer, vol.11, 2019 (Peer-Reviewed Journal)

XVI. Recent advances in cancer stem cell targeted therapy

AKBULUT H., BABAHAN C., Abgarmi S. A., Ocal M., Besler M.

Critical Reviews in Oncogenesis, vol.24, no.1, pp.1-20, 2019 (Scopus)

XVII. Risk factors for thrombosis risk in patients with cancer

TURAN D., YAŞAR H. A., Aksu O. B., KÖKSOY E. B., UTKAN G., AKBULUT H., ÜRÜN Y.

Journal of Oncological Sciences, vol.4, no.3, pp.130-133, 2018 (Peer-Reviewed Journal)

XVIII. Cancer patient and hunger

Mizrak D., AKBULUT H.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.30, no.3, pp.152-157, 2015 (ESCI)

- XIX. **Assessment of immature teratoma by 18F-FDG PET/CT**
ÖZKAN E., Yagci S., Dogan M., Lacin S., KÜÇÜK N. Ö., AKBULUT H.
European Journal of Radiology Extra, vol.78, no.3, 2011 (Scopus)
- XX. **Kolon kanserinde gen tedavisi**
BAYDIN P., AKBULUT H.
Türkiye Klinikleri Tıbbi Onkoloji, vol.2, no.1, pp.83-90, 2009 (Peer-Reviewed Journal)
- XXI. **The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer**
Buyukcelik A., AKBULUT H., Yalqin B., Encan O., Tek J., Demir O., DEMİRKAZIK A., Djnqol D., Onur H., Icli F.
Turkish Journal of Cancer, vol.38, no.4, pp.175-183, 2008 (Scopus)
- XXII. **The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study**
Yalçin B., Zengin N., AYDIN F., İlhan M., Işıkdoğan A., Demir G., Aykan F., ÇELİK İ., Dane F., Üstüner Z., et al.
Turkish Journal of Cancer, vol.36, no.3, pp.108-115, 2006 (Scopus)
- XXIII. **The efficacy of preoperative cisplatin and 5-flourouracil combination in patients with stage III squamous cell carcinoma of the esophagus**
Han S., Yalçin B., AKBULUT H., Ökten I.
Turkish Journal of Cancer, vol.35, no.1, pp.26-31, 2005 (Scopus)
- XXIV. **Frequency of symptoms in patients with advanced cancer**
Yalçin B., Büyükçelik A., Şenler F. Ç., UTKAN G., Tek I., Doğan M., Doruk H., DEMİRKAZIK A., AKBULUT H., Icli F.
Turkish Journal of Cancer, vol.35, no.4, pp.177-180, 2005 (Scopus)
- XXV. **The opinions of the cancer patients about pain management: A questionnaire study**
Yalçin B., Şenler F. Ç., Büyükçelik A., UTKAN G., Tek I., Doruk H., AKBULUT H., Icli F.
Turkish Journal of Cancer, vol.34, no.3, pp.114-117, 2004 (Scopus)
- XXVI. **Radiation recall effect with docetaxel: Is it a barrier for sandwich approach of radiotherapy sequencing in adjuvant breast cancer treatment?**
Samur M., Garipağaoğlu M., AKBULUT H.
Turkish Journal of Cancer, vol.31, no.2, pp.82-86, 2001 (Scopus)
- XXVII. **Relationship between serum concentration of vascular endothelial growth factor and tumor stage in breast cancer patients**
Eroglu A., Demirkazik A., AKBULUT H., Eroglu N.
Journal of B.U.ON., vol.4, no.1, pp.83-85, 1999 (Scopus)
- XXVIII. **Cardiotoxicity of 5-fluorouracil: Two cases with severe bradycardia and review of the literature**
Samur M., Arican A., Cakir M., Sencan O., DEMİRKAZIK A., AKBULUT H., Icli F.
Turkish Journal of Cancer, vol.29, no.1, pp.39-41, 1999 (Scopus)
- XXIX. **The clinical value of flow cytometric DNA content analysis in patients with soft tissue sarcomas**
Samur M., Pamir A., AKBULUT H., Ereku S., Sağlık Y., YILDIZ Y., Dinçol D., Icli F.
Sarcoma, vol.3, no.3-4, pp.171-175, 1999 (Scopus)
- XXX. **Myeloprotective effect of high dose medroxyprogesterone acetate on patients receiving cytotoxic chemotherapy**
Samur M., Icli F., AKBULUT H., DEMİRKAZIK A., Cay F., Arican A.
Turkish Journal of Cancer, vol.28, no.3, pp.118-123, 1998 (Scopus)
- XXXI. **The prognostic significance of flow cytometric cellular DNA content determination in patients with colorectal carcinoma**
AKBULUT H., Dincol D., Aydintug O., Icli F., Karaoguz H., DEMİRKAZIK A., Cay F., AYDIN F. G.
Turkish Journal of Cancer, vol.28, no.2, pp.51-58, 1998 (Scopus)

Books & Book Chapters

I. Kanser Biyolojisi

Babahan C., Sonugür F. G., Akbulut H.

in: İç Hastalıkları, İliçin Gürler, Biberoglu Kadir, Süleymanlar Gültekin, Ünal Serhat, Editor, Güneş Tıp Kitabevi, Ankara, pp.1659-1670, 2024

II. Viral Vektör Aşıları

Sonugür F. G., Babahan C., Akbulut H.

in: Aşı Çalışmaları ve Teknolojisi, Mert Döşkaya, Adnan Yüksel Gürüz, Ayşe Gülten Kantarcı, Cemal Ün, Editor, Nobel Tıp Kitabevi, Ankara, pp.355-382, 2023

III. Hedefe Yönelik Ajanlar ve COVID-19

Köksoy E. B., Akbulut H.

in: Kanser ve COVID-19 Pandemisi, Yalçın Ş, Özet A, Editor, Türkiye Klinikleri, Ankara, pp.95-100, 2020

IV. Cancer Gene Therapy

Aktaş S. H., Baydın P., Akbulut H.

in: Cancer, Prof. Dr. Mustafa Altınbaş, Editor, DNT Ortadoğu Yayıncılık, Ankara, pp.1372-1383, 2016

V. Prevention of Cervical Cancer: Chemoprevention

Akbulut H., Deisseroth A.

in: Progress in Oncology 2002, DeVita V, Hellman S, Rosenberg SA, Editor, Jones and Barlett Publishers, Massachusetts, pp.251-269, 2002

Refereed Congress / Symposium Publications in Proceedings

I. Increased Expression of DNA Damage Inducible Transcript 4 Gene is Associated with Poor Prognosis and "Right-Sidedness" in Colorectal Cancer

demir f. g., TAMAM S., ÇULCU S., SAVAŞ B., AKBULUT H., ÖZDAĞ SEVGİLİ H., BELDER N.

How to bring basic science discoveries to the clinic, 27 February 2024

II. INHBA is a potential biomarker and therapeutic target for patients with colorectal cancer

BELDER N., DEMİRKOL CANLI S., TAMAM S., ÇULCU S., SAVAŞ B., AKBULUT H.

November 29 – December 02, 2023 9 th International BAU Drug Design Congress, 29 November - 02 December 2023

III. Low-Dose Chemotherapy Inhibits Proangiogenic Factors in Endothelial and Cancer Cells

SONUGÜR F. G., BABAHAH C., AKBULUT H.

BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 28 - 30 September 2023

IV. Replication Defective Adenoviral Vectors Decreases the Immunosuppressive Cytokine Expression in Tumor Cells

Zengin İ., SONUGÜR F. G., BABAHAH C., Abdi Abgarmi S., AKBULUT H.

BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 28 September 2023

V. Replication Defective Adenoviral Vectors do not induce Apoptosis and Autophagy in endothelial cells

Korgan E., BABAHAH C., SONUGÜR F. G., Abdi Abgarmi S., AKBULUT H.

BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 28 September 2023

VI. Purification Optimization Of A Recombinant Single-Chain Variable Fragment (ScFv) Antibody

BABAHAH C., SONUGÜR F. G., KARAGÖZ Z., YILMAZ E., AKBULUT H.

BIOTürkiye, İstanbul, Turkey, 28 - 30 September 2023

VII. Nadir Meme Kanseri Tipleri - Tek Merkez Deneyimi

YAŞAR H. A., KUBİLAY TOLUNAY P., AKBULUT H.

On Targed Master Oncology, Muğla, Turkey, 21 - 24 September 2023, pp.43-44

VIII. GİST HASTALARINDA İMATİNİB ALTINDA KAN LİPİD DÜZEYİ DEĞİŞİKLİKLERİ

KÖKSOY E. B., KARCI E., ÜRÜN M., YAŞAR H. A., ÖZYURT N., UTKAN G., AKBULUT H.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.441

IX. DOWNSTREAM PROSES SÜRECİNDE İNKÜBASYON SICAKLIĞI VE MİKROFİLTASYON MEMBRANI SEÇİMİNİN REKOMBİNANT ADENOVİRAL VEKTÖR VERİMİNE ETKİSİ

SONUGÜR F. G., BABAHAH C., Abdi Abgarmi S., AKBULUT H.

4.Uluslararası Aşı Bilimi Kongresi, Ankara, Turkey, 03 November 2022, vol.1, pp.1

- X. **İLERİ EVRE MALİGNİTELERDE İMMÜNCHECKPOINT İNHİBİTÖRLERİ İLE EŞ ZAMANLI VERİLEN ANTİHİSTAMİNİKLERİN SAĞKALIM KATKISI İLE İLGİLİ GERÇEK YAŞAM VERİLERİ**
Eylemer Mocan E., Yekedüz E., Karataş G., Yazgan S. C., Köksoy E. B., Çay Şenler F., Utkan G., Demirkazık A., Akbulut H., Ürün Y.
9. TÜRK TIBBİ ONKOLOJİ DERNEĞİ KONGRESİ, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.53-54
- XI. **Sirolimus Kemopreventif Tedavisi Altındaki Bir PTEN Hamartom Sendromu Olan Bannayan-Riley-Ruvalcaba Sendromu**
Eylemer Mocan E., Köksoy E. B., Akbulut H.
9. Türk Tıbbi Onkoloji Derneği Kongresi , Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.196
- XII. **The impact of COVID-19 pandemic on cancer care: A global collaborative study**
Jazieh A. R., AKBULUT H., Curigliano G., Rogado A., Alsharm A. A., Razis E., Mula-Hussain L. Y. I., Errihani H., Khattak A., De Guzman R. B., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- XIII. **The Effect of PD-L1 Expression on Angiogenesis and Invasion in Tumor Cells**
BABAHAN C., Abdi Abgarmi S., SONUGÜR F. G., AKBULUT H.
Immuno-Oncology 2019, Barselona, Spain, 23 May 2019, pp.6-7
- XIV. **Oxidative Stress and Sirtuin2 Changes in Different Partsof the Brain in Aging: Protective Effect of Melatonin**
AKBULUT K. G., KESKİN AKTAN A., Abgarmi S. A., AKBULUT H.
Turkish Society of Physiological Sciences 45th National Physiology Congress Kuşadası-Aydın, Turkey, 31 October - 03 November 2019
- XV. **Meme Kanserinde Survivin İfadesinin Tamoksifen Direncine Etkisi**
DEDE İ., AKBULUT H., KARABÖRK A., ÇETİN Ş.
4th International Symposium on Innovative Approaches in Health and Sports Sciences Proceedings, 22 - 24 November 2019
- XVI. **The role of pericytes on the efficacy of Bevacizumab in colorectalcancer**
Bakırcı M., dost günay f. s., ÇAY ŞENLER F., kırmızı a. b., SAVAŞ B., AKBULUT H.
7th International Congress of Molecular Medicine, 5 - 07 September 2019
- XVII. **The role of pericytes on the efficacy of Bevacizumab in colorectal cancer**
Besler M., Dost Günay F. S., ÇAY ŞENLER F., KIRMIZI B. A., SAVAŞ B., AKBULUT H.
VII. International Congress of Molecular Medicine, 5 - 07 September 2019
- XVIII. **Anti-Angiogenic Treatment Suppresses the Immunosuppressive Cytokine Production in Tumor Cells**
Abdi Abgarmi S., BABAHAN C., SONUGÜR F. G., AKBULUT H.
Immuno-Oncology 2019, Barselona, Spain, 23 May 2019
- XIX. **Setüksimab tedavisi ile uzun süre stabil seyretmiş cilt SCC olgusu**
ÖZYURT N., GÜRBÜZ M., YAŞAR H. A., KUBİLAY TOLUNAY P., YEKEDÜZ E., KARAALIOĞLU B., AKBULUT H.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.401
- XX. **Nodüler Lenfosit Baskın Hodgkin Lymphoma (NLBHL)'da Kombine İnflamasyon İndeksinin Prognostik Önemi**
PAYDAŞ S., ÇAKAR M. K., BARIŞTA İ., SEYDAOĞLU G., PEHLİVAN M., DOĞAN M., ALTUNTAŞ F., CİVRİZ BOZDAĞ S., ÜNAL A., YILDIZ B., et al.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019
- XXI. **Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dose Taksel Tedavi Sonuçları- Gerçek Yaşam Verisi**
ALKAN A., SEVGİN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.185
- XXII. **GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTi- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ**
ALKAN A., SEVGİN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., AKIN TELLİ T., KESKİN Ö.,

ARSLAN Ç., BİLGİN B., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.300

XXIII. Nazofarenks Kanseri Hastalarda Sağkalım İle İlişkili Prognostik Faktörler

YAŞAR H. A., KUBİLAY TOLUNAY P., DEMİRKIRAN A., KARAAĞAÇ M., GÜMÜŞTEPE E., UTKAN G., ARTAÇ M., AKBULUT H.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019

XXIV. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dositaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.

23. Ulusal Kanser Kongresi - 2019, Turkey, 17 - 21 April 2019

XXV. GERIATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİ METASTATİK PROSTAT KANSERİ (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.

23. ULUSAL KANSER KONGRESİ - 2019, Turkey, 17 - 21 April 2019

XXVI. Start of a new Arms Race? The US nuclear Arms Policy in the Trump era

AKBULUT H.

Conference on Radical Break?- American Foreign Policy in the Era of Donald Trump, Tutzing, Germany, 15 - 17 December 2017, vol.15, pp.153-186

XXVII. Neuroprotective Effects of Sirt2 Inhibition in Aging

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.

Turkish Society of Physiological Sciences 44, Antalya, Turkey, 1 - 04 November 2018

XXVIII. SIRT2 inhibition suppresses the oxidative stress andapoptotic activity, and increases autophagy of cerebrcortex in the aging process.

AKBULUT K. G., KESKİN AKTAN A., Abgarmı S., AKBULUT H.

14-16 September 2018The QEII Centre, London, UK, Londrina, Brazil, 14 - 16 September 2018

XXIX. Age-related changes in the oxidative stress, apoptosis,sirtuin 2 and FoxO3a expression in the hippocampus:protective effects of melatonin

KESKİN AKTAN A., Abgarmı S., AKBULUT K. G., AKBULUT H.

14-16 September 2018The QEII Centre, London, UK, 14 - 16 September 2018

XXX. MİDE KANSERİ VE ABO KAN GRUBU İLİŞKİSİ: ÇOK MERKEZLİ, GÖZLEMSEL, VAKA-KONTROL ÇALIŞMASI

YAŞAR H. A., UTKAN G., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., DEDE İ., ÜRÜN Y., AKBULUT H.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.443

XXXI. A bicistronic adenoviral vector carrying cytosine deaminase and GM-CSF genes significantly improves antitumor immunity and overall survival in colon cancer

AKBULUT H., ÇÖLERİ CİHAN A., ŞAHİN G., Tang Y., Deisseroth A., Icli F.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, United States Of America, 14 - 18 April 2018, vol.78

XXXII. The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

AKBULUT H., Öçal M., Sonugür F. G., Babahan C., Abdi Abgarmı S.

ASCO 2018, 1 - 04 June 2018

XXXIII. Pankreas Kanseri ve ABO Kan Grubu İlişkisi: Çok Merkezli, Gözlemsel, Vaka-Kontrol Çalışması

KÖKSOY E. B., UTKAN G., ERGÜN Y., ESİN E., ŞENDUR M. A. N., KARCI GÜNER E., DEDE İ., DEMİRCİ N. S., SEZER A., ENGİN H., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018

XXXIV. İPİLİMUMAB İLE TEDAVİ EDİLEN MUKOZAL VE UVEAL MALIGN MELANOM HASTALARINDA SAĞKALIM İÇİN PROGNOSTİK FAKTÖRLER: TÜRK ONKOLOJİ ÇALIŞMA GRUBU (TOG) ÇALIŞMASI

YAŞAR H. A., TURNA Z. H., ESİN E., SEDEF A. M., ALKAN A., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., ŞENDUR M. A.

N., SEZER A., KILIÇKAP S., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.150

XXXV. METASTATİK OLMAYAN KOLOREKTAL ADENOKANSERDE HASTALIKSIZ SAĞKALIM İLE İLGİLİ PREDİKTİF FAKTÖRLERİN DEĞERLENDİRİLMESİ

KARCI E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., YAŞAR H. A., MÜSLİH Ü., ÖZYURT DOĞAN N., ÖZDEMİR N., ŞENDUR M. A. N., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018

XXXVI. Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

Yalcin S., Dane F., Oksuzoglu B., Yildirim N., Isikdogan A., Ozkan M., Demirag G., Coskun H. S., Karabulut B., EVRENSEL T., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36

XXXVII. Relationship between metabolic parameters and ras mutation status

KARCI E., SOYDAL Ç., UTKAN G., ÜRÜN Y., AKBULUT H.

30th Annual Congress of the European Association of Nuclear Medicine, 21 - 25 October 2017, vol.44, pp.696

XXXVIII. Oxidative stress, FOXO3a andBIM expressions in aging cerebral cortex: modulation by curcumin

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.

2ndInternational Gazi Pharma Symposium Series (GPSS-2017), October 11-13, 2017, GaziUniversity, Turkey. P, 11 - 13 October 2017

XXXIX. The effects of curcumin administration on hippocampal SIRT2 , BCL-2 BAX and BIM expression in young and aged rats.

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.

43. Ulusal Fizyoloji Kongresi, Turkey, 7 - 09 September 2017

XL. Significance of tumour-infiltrating lymphocytes (TILs) in gastric carcinomas: Association of PD-L1 and PD-1 expression with prognostic parameters and survival

Arman F., YAŞAR H. A., SAVAŞ B., AKBULUT H., ENSARİ A.

European Congress of Pathology, 2 - 06 September 2017, vol.471, pp.34-35

XLI. Effect of verylow doses of cehmotherapeutic drugs on proangiogenic factors in tumor cells

Öçal M., Sonugür F. G., Babahan C., Abdi Abgarmi S., İÇLİ F., AKBULUT H.

ASCO 2017, 2 - 06 June 2017

XLII. Asingle center analysis of evolving experience with ALPPS procedure: Towards better patient and graft selection

BALCI D., KIRIMKER E. O., ÖZÇELİK M., ÜSTÜNER E., KONCA C., UTKAN G., AKBULUT H., ÜRÜN Y., ÇAY ŞENLER F., DEMİRKAZIK A., et al.

12th Biennial E-AHPBA Congress 2017, Mainz, Germany, 23 - 26 May 2017

XLIII. Effect of very low doses of chemotherapeutic drugs on proangiogenic factors in tumor cells.

Ocal M., Sonugur F. G., BABAHAN C., Abgarmi S. A., Icli F., AKBULUT H.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35

XLIV. Tumor associated macrophages to predict the efficacy of bevacizumab plus chemotherapy in patients with advanced colorectal cancer.

AKBULUT H., Gunay F. S. D., Kirmizi B. A., Koksoy E. B., ENSARİ A., Icli F.

53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35

XLV. The effects of very low doses of chemotherapeutic drugs on endothelial cells.

Sonugur F. G., Ocal M., BABAHAN C., Abgarmi S. A., Icli F., AKBULUT H.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35

XLVI. Metronomik Kemoterapinin Tümör Hücrelerinde Anjiyogenik Faktör Sentezi Üzerindeki Etkileri

ÖÇAL DEMİRTAŞ M., SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 23 April 2017

XLVII. Onkoloji pratiğinde aşılama ve etkileyen faktörler

ALKAN A., KARCİ E., YAŞAR H. A., TUNCAY G., KÖKSOY E. B., ÜRÜN M., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., AKBULUT H., et al.

22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017

XLVIII. Kalp ve Beyin Metastatik Yassı Hücreli Dil Karsinomu Olgusu

ÜRÜN M., ÖZYURT N., KÖKSOY E. B., YAŞAR H. A., KARCİ E., UTKAN G., AKBULUT H.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.321

XLIX. Metronomik Kemoterapinin Endotel Hücre Fonksiyonları Üzerindeki Etkisi

SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017

L. Evre III Mide kanseri adjuvant tedavisinde dosetaksel- sisplatin- fluorourasil(DCF) rejiminin etkinliği

ALKAN A., Mızrak D., KARCİ E., YAŞAR H. A., KÖKSOY E. B., ÜRÜN M., Kütük T., ÜRÜN Y., ÇAY ŞENLER F., AKYÜREK S., et al.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.256-257

LI. Metastatik Olmayan Kolorektal Adenokanserlerde Lenf Nodu Metastazı İçin Prediktif Faktörlerin Değerlendirilmesi

KARCİ E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., DEDE İ., TUNCAY G., YAŞAR H. A., ÜRÜN M., ÖZYURT DOĞAN N., et al.

22. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 April 2017, pp.242-243

LII. Evre III Mide Kanseri Adjuvant Tedavisinde Dosetaksel-Sisplatin-Fluorourasil (DCF) Rejiminin Etkinliği

ALKAN A., MIZRAK KAYA D., Karcı E., Yasar A., Koksoy E. B., Ürün M., Kütük T., Özyurt N., ÜRÜN Y., ÇAY ŞENLER F., et al.

22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017

LIIL. Prognostic importance of bone marrow uptake on baseline 18F-FDG positron emission tomography/computed tomography in diffuse large B-Cell lymphoma

SOYDAL Ç., KÖKSOY E. B., YAŞAR H. A., TURGAL E., DOĞANAY ERDOĞAN B., AKBULUT H., KÜÇÜK N. Ö.

Annual Congress of the European Association of Nuclear Medicine, 15 - 19 October 2016, vol.43, pp.317

LIV. Medical oncologists attitudes towards vaccination in oncology practice

ALKAN A., KARCİ E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.

ESMO Congress, 7 - 11 October 2016

LV. The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer mCRC

AKBULUT H., Öcal M., Sonugür G., AKAY B., Bahahan C., Abgarmi S. A., DEMİRKAZIK A., İÇLİ F.

ESMO Congress, 7 - 11 October 2016

LVI. TRPredictive factors of lymph node metastasis in patients with non metastatic colorectal Adenocarcinoma

Karcı E., KÖKSOY E. B., ALKAN A., Dede İ., Tuncay G., UTKAN G., ÜRÜN Y., AKBULUT H.

ESMO Congress, 7 - 11 October 2016

LVII. Vaccination in oncology practice and predictors

ALKAN A., KARCİ E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.

ESMO, 7 - 10 October 2016

LVIII. Medical oncologists attitudes towards vaccination in oncology practice

ALKAN A., KARCİ E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.

ESMO annual meeting, 7 - 11 October 2016

LIX. Predictive factors of lymph node metastasis in patients with non-metastatic colorectal

adenocarcinoma

Karci E., Koksoy E. B., Alkan A., Dede I., Tuncay G., Utkan G., ÜRÜN Y., AKBULUT H.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27

- LX. **Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxelcisplatin-fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer**
Alkan A., Mizrak D., Karci E., Yasar A., Koksoy E. B., Urun M., Kutuk T., Urun Y., Senler F. C., Akyurek S., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016
- LXI. **Severe Drug Interactions and Potentially Inappropriate Medication Usage in Elderly Cancer Patients**
ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ÜRÜN M., ÇAY ŞENLER F., ÜRÜN Y., ERGUN H., AKBULUT H.
ASCO, 6 - 10 June 2016
- LXII. **Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors ORTHUS study A study of the palliative care working committee of the Turkish Oncology Group TOG**
ALKAN A., Güç Z. G., ÇAY ŞENLER F., YAVUZŞEN T., Onur H., Doğan M., Karci E., YAŞAR H. A., KÖKSOY E. B., TANRIVERDİ Ö., et al.
Annual Meeting of ASCO, United States Of America, 1 - 04 June 2016
- LXIII. **Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors (ORTHUS study): A study of the palliative care working committee of the Turkish Oncology Group (TOG).**
Alkan A., Guc Z. G., Senler F. C., YAVUZŞEN T., Onur H., Dogan M., Karci E., Yasar A., Koksoy E. B., Tanriverdi O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- LXIV. **Mesenchymal stem cell directed baculoviral gene therapy of colon cancer.**
Akbulut H., Aktas S. H., Elçin A. E., Parmaksız M., Keskin A. A., Cihan A. C., Elçin Y. M., Icli F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- LXV. **Severe drug interactions and potentially inappropriate medication usage in elderly patients with cancer.**
Alkan A., Yasar A., Karci E., Koksoy E. B., Urun M., Senler F. C., ÜRÜN Y., Ergun H., AKBULUT H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- LXVI. **Nadir bir vaka: Akciğer ve kolonda senkron multiple primer tumor**
YAŞAR H. A., budak B., ALKAN A., AKBULUT H.
6. Türk Tıbbi Onkoloji kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.454
- LXVII. **Tam Remisyondaki opere meme kanseri hastalarında postmastektomi ağrı sendromu ile post traumatic stress bozukluğu ilişkisi (ORTHUS Çalışması)- Tük Onkoloji Grubu Destek Tedaviler Grubu**
ALKAN A., Güç Z. G., ÇAY ŞENLER F., YAVUZŞEN T., onur H., Doğan M., karci E., YAŞAR H. A., KÖKSOY E. B., TANRIVERDİ Ö., et al.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.142
- LXVIII. **Geriatrik kanser hastalarında ciddi ilaç etkileşimi ve uygunsuz ilaç kullanımı**
ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ürün m., ÇAY ŞENLER F., ÜRÜN Y., TUNCAY G., ERGÜN H., AKBULUT H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.167
- LXIX. **The Effect of Melatonin Curcumin and Salermide on Sirt2 expression Level of Hippocampus in Middle Aged Rats**
AKBULUT K. G., KESKİN AKTAN A., Mutlu Ç., AKBULUT H.
41st National Physiology Congress, Turkey, 12 - 14 September 2015
- LXX. **Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study**

ÜRÜN Y., Abali H., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N. Y., Sendur M. A. N., Sezer A., et al.
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51

- LXXI. **Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.**

AKBULUT H., Gercik O., Icli F., Mizrak D., DEMİRKAZIK A., Onur H., Senler F. C., Utkan G.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- LXXII. **The survival rate at 5 years in Turkish metastatic melanoma patients treated with ipilimumab: Final analysis of MIPI-TURK**

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Mandel N. M., Demir G., Gokmen E., Paydas S., AKBULUT H., ÇELİK İ.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- LXXIII. **The significance of the serum leptin, ghrelin, tumor necrosis factor alpha and interleukine-1 levels in patients with non-small cell lung cancer**

Karatas F., Yalcin B., AKBULUT H., Utkan G., Sahin S., DEMİRKAZIK A., Hacıoglu B., Icli F.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- LXXIV. **4 1 7 Endüstri ve Teknoloji Kanser Araştırmaları ve tedavilerini ne kadar etkiliyor**

AKBULUT H.

Ulusal Kanser kongresi, Turkey, 25 - 27 April 2015

- LXXV. **Nutrition foods poultry meat and cancer**

AKBULUT H.

Third international poultry meat congress, 22 - 26 April 2015

- LXXVI. **Preoperative systemic therapy for locally advanced breast cancer single center experience**

MIZRAK KAYA D., Kubilay P., Berna K., Onur H., AKBULUT H.

San Antonio Breast Cancer Conference, 9 - 13 December 2014

- LXXVII. **Effect of HER2 and hormonal status to FDG uptake on PET CT imaging in recurrent breast cancer**

MIZRAK KAYA D., Onur h., öztürk b., pınar k., UTKAN G., AKBULUT H.

SanAntonio Breast Cancer Conference, 9 - 13 December 2014

- LXXVIII. **More prognostic factors in early stage breast cancer**

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.

san Antonio Breast Cancer Conference, 9 - 13 December 2014

- LXXIX. **Serum levels of CEA and CA 15 3 in different subtypes of recurrent breast cancer**

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.

San Antonio Breast Cancer Conference, 9 - 13 December 2014

- LXXX. **Effect of tumor hormonal and HER2 status on localization of metastases in recurrent breast cancer**

MIZRAK KAYA D., Onur H., Öztürk B., Kubilay P., AKBULUT H.

San Antonio Breast Cancer Conference, 9 - 13 December 2014

- LXXXI. **Blood group is it associated with tumor biology in breast cancer**

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.

San Antonio Breast Cancer Conference, 9 - 13 December 2014

- LXXXII. **Correlation of tumor marker levels with intensity of FDG uptake on PET imaging in epithelial cancers.**

Mizrak D., ARAZ M., AKBULUT H., KÜÇÜK N. Ö., Alkan A., Yalcin S., Icli F.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- LXXXIII. **Over kanserli hastalarda serum CA125 düzeyi ile 18F-FDG-PET/BT pozitifliği arasındaki ilişkinin**

saptanması

Mızrak D., ARAZ M., AKBULUT H., Kubilay P., ALKAN A., KÜÇÜK N. Ö., İÇLİ F.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

LXXXIV. Metastatik kolorektal kanserli hastalarda serum CEA düzeyleri ile 18F- FDG-PET/BT pozitifliği ilişkisi

Mızrak D., ARAZ M., ALKAN A., AKBULUT H., KÜÇÜK N. Ö., İÇLİ F.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

LXXXV. Meme kanserli hastalarda serum CEA ve CA 15-3 düzeyleri ile 18F-FDG PET/BT pozitifliği arasındaki ilişki

Mızrak D., ARAZ M., AKBULUT H., ÖZTÜRK B., ALKAN A., KÜÇÜK N. Ö., İÇLİ F.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

LXXXVI. Is anemia due to chronic disease the main cause of anemia in cancer patients?

Utkan G., Kenar G., AKBULUT H., DEMİRKAZIK A., Onur H., İcli F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31

May - 04 June 2013, vol.31

LXXXVII. Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up.

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., AKBULUT H., ÇELİK İ.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31

May - 04 June 2013, vol.31

LXXXVIII. Serum CEA and CA 15-3 levels according to breast cancer subtypes

Dede I., Utkan G., AKBULUT H., ÜRÜN Y., Mızrak D., İcli F.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

LXXXIX. The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen.

Aktas S. H., AKBULUT H., Yazici O., Zengin N., Akgun N., Ustuner Z., İcli F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31

May - 04 June 2013, vol.31

XC. Wnt1 gene expression alters heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133(+)/CD44(+)prostate cancer stem cells

Goksei G., Bilir A., Uslu R., AKBULUT H., Guven U., ÖKTEM G.

104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, Kiribati, 6 - 10 April 2013, vol.73

XCII. FIGHTING AGAINST CIGARETTE SMOKING AMONG MEDICAL STUDENTS-A SUCCESS STORY

İcli F., ODABAŞ D., Gonullu İ., AKBULUT H., Ozkan A., Olmez S., Gonullu U., Sunguroglu K.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, pp.469

XCII. Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., AKBULUT H., Celik I.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

XCIII. ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

ÜRÜN Y., Koru-Sengul T., Altundag K., Utkan G., Onur H., AKBULUT H., DEMİRKAZIK A., İcli F.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

XCIV. Smoking habits of relatives of patients (pts) with cancer.

Hayran M., Kilickap S., ELKIRAN E. T., AKBULUT H., Abali H., Yuce D., Kilic D., Turhal S.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

- XCV. The Significance of the Serum Leptin Ghreline Tumor Necrosis Factor Alpha and Interleukine 1 Levels in Patient With Non Small Cell Lung Cancer**
 ÜRÜN Y., YALÇIN B., KARATAŞ F., UTKAN G., YÜKSEL C., CANGIR A., ÇAY ŞENLER F., DEMİRKAZIK A., AKBULUT H., İÇLİ F., et al.
 The 2011 European Multidisciplinary Cancer Congress. Stockholm, Sweden, Stockholm, Sweden, 24 - 27 September 2011, pp.612
- XCVI. Status of Granulocyte Colony-Stimulating Factor Receptor in Tumour Tissue of Patients With Breast Cancer**
 Yalcin B., Gunaydin Y., Percinel S., Dogan M., ÜRÜN Y., Ozal F. G., Utkan G., AKBULUT H., Icli F., Sencan O.
 European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- XCVII. The Significance of the Serum Leptin, Ghreline, Tumour Necrosis Factor Alpha and Interleukine-1 Levels in Patients With Non-Small Cell Lung Cancer**
 ÜRÜN Y., Yalcin B., Karatas F., Utkan G., YÜKSEL C., Cangir A., Senler F. C., DEMİRKAZIK A., AKBULUT H., Icli F., et al.
 European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- XCVIII. Relationship Between ABO and RH Blood Groups and K-Ras Phenotype in Patients With Colorectal Adenocarcinoma**
 ÜRÜN Y., Utkan G., Arslan O., AKBULUT H., Savas B., Senler F. C., Onur H., Yalcin B., DEMİRKAZIK A., Icli F.
 European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- XCIX. The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.**
 YAZICI O., AKBULUT H., Akgün N., UTKAN G., YALÇIN B., İÇLİ F.
 ASCO 2011, 2 - 06 June 2011
- C. Melatonin Decreases DNA Fragmentation and Oxidative STRESS PARAMETERS of Gastrointestinal Mucosa**
 AKBULUT K. G., AKBULUT H., Akgun N.
 9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.99-100
- CI. The Chemotherapeutic DRUGS at the Metronomic Doses Decrease Vascular ENDOTHELIAL GROWTH FACTOR (VEGF) Secretion of SOLID TUMORS**
 Aktas H. E., AKBULUT H., Akgun N.
 9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.162-163
- CII. The role of Phe329 in the inhibition of human butyrylcholinesterase by malachite green and methyl green**
 Biberoglu K., Tacal O., AKBULUT H.
 35th Congress of the Federation-of-European-Biochemical-Societies, Gothenburg, Sweden, 26 June - 01 July 2010, vol.277, pp.81
- CIII. Inhibition of A277V mutant of human butyrylcholinesterase by malachite green**
 Biberoglu K., Tacal O., AKBULUT H.
 34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Czech Republic, 4 - 09 July 2009, vol.276, pp.130
- CIV. GM CSF augments tumor specific immune response and anti tumoral efficacy when combined with suicide gene therapy**
 AKBULUT H., ÇÖLERİ CİHAN A., AÇIKGÖZ N., ŞAHİN G., BAYDIN P., TANG Y., İÇLİ F., DEISSEROTH A.
 45th ASCO Annual Meeting, Orlando, 29 May - 02 June 2009, vol.27
- CV. Effect of GM-CSF on tumor-specific immune response and antitumoral efficacy when combined with suicide gene therapy**
 AKBULUT H., Coleri A., Acikgoz N., Sahin G., Ozkal P., Tang Y., Icli F., Deisseroth A.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

- CVI. **Kronik Viral Hepatitlerde Lenfoproliferatif Hastalıklar**
BOZKUŞ Y., İDİLMAN R., MIZRAK KAYA D., CENGİZ SEVAL G., Saykı M., Üstün Y., DOĞANAY ERDOĞAN B., BEKTAŞ M., ÇINAR K., ARAT M., et al.
25. Ulusal Gastroenteroloji Haftası, Turkey, 12 - 16 November 2008
- CVII. **Vector Prime-Protein Boost Vaccine induces 20 Fold Decrease in the Levels of CD44(+)CD24(-/Low) Cancer Stem Cells in Epithelial Neoplasms**
Tang Y., AKBULUT H., Maynard J., Li P., Deisseroth A. B.
50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium, San-Francisco, Costa Rica, 6 - 09 December 2008, vol.112, pp.1000
- CVIII. **TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia**
Tang Y., Park Y. H., Maynard J., Li P., AKBULUT H., Petersen L., Deisseroth A. B.
50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2008, vol.112, pp.141-142
- CIX. **Vaccine for prevention of breast cancer.**
Deisseroth A., Tang Y., Maynard J., AKBULUT H.
42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Georgia, United States Of America, 2 - 06 June 2006, vol.24
- CX. **Vector targeted chemotherapy plus vector vaccination can cure solid tumors**
AKBULUT H., Tang Y., Akbulut G. K., Maynard J., Deisseroth A. B.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.143
- CXI. **Hepatitis B and C seroprevalance in cancer patients: A case control study**
Utkan G., Azap A., Muallaoglu S., Tokluoglu S., Durnali A. G., Arslan U. Y., Kocer M., Celenkoglu G., AKBULUT H., Alkis N.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.297
- CXII. **Vector prime-protein boost vaccine induces immune response against "self-antigens" associated with epithelial neoplasms and tumor vascular endothelial cells.**
Tang Y., Maynard J., AKBULUT H., Linton P., Deisseroth A.
47th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 10 - 13 December 2005, vol.106
- CXIII. **Irinotecan plus oral etoposide (IRET) combination is an highly active and promising treatment in heavily pre-treated small cell lung cancer patients.**
AKBULUT H., Tek I., Demirkazik A., Icli F., Doruk H., Yalcin B., Utkan G., Buyukcelik A.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXIV. **The evaluation of the hydrotalcite effectiveness on prophylaxis and treatment of mucositis due to high dose methotrexate treatment in osteosarcoma patients: A prospective crossover trial.**
Utkan G., Tek I., Doruk H., Yalcin B., Buyukcelik A., AKBULUT H., Demirkazik A., Icli F., Pamir A.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXV. **The relationship between serum cholesterol level and axillary lymph node statu in breast cancer patients**
Utkan G., Onur H., Akbulut H., Yalcin B., Buyukcelik A., Tek I., Doruk H., Dogan M., Demirkazik A., Icli F.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2005, vol.94
- CXVI. **Divided doses of cisplatin in combination with gemcitabine for patients with advanced non-small cell lung cancer (NSCLC).**

Demirkazik A, Yalcin B., AKBULUT H., Buyukcelik A., Cay F., Utkan G., Icli F.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

- CXVII. **Addition of 2 cycles of EP (Etoposide plus Cisplatin) to the 4 cycles of adjuvant AC (doxorubicin plus cyclophosphamide) improves the survival in node positive patients with breast cancer after 10 years**

Icli F., AKBULUT H., Dincol D., Onur H., Demirkazik A., Cam R., Cay F., Demirci S., Uner A., Ereku S.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

- CXVIII. **The prognostic role of serum telomerase activity in advanced breast cancer receiving anthracyclines.**

AKBULUT H., Temizkan S., Arican A., Zengin N., Yalcin B., Icli F.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

- CXIX. **Vector vaccine overcomes anergy.**

Deisseroth A., Tang Y., Zhang L., AKBULUT H., Linton P.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

- CXX. **An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells**

zhang l, Tang Y., AKBULUT H., Zeltermann D., linton P., Deisseroth A.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, 6 - 08 December 2003

- CXXI. **An adenoviral vector cancer vaccine that delivers a tumor associated antigen/CD40-ligand fusion protein to dendritic cells in vivo and thereby breaks tolerance to tumor associated self antigens.**

Tang Y., Zhang L., AKBULUT H., Litton P., Deisseroth A.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

- CXXII. **Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies**

Idilman R., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Soydan E., Ozcan M., BEKSAÇ M., Arslan O., Akbulut H., et al.

38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April 2003, vol.38, pp.146-147

Metrics

Publication: 325

Citation (WoS): 1496

Citation (Scopus): 1846

H-Index (WoS): 21

H-Index (Scopus): 23